Loading
A phase 2 trial of Belzupacap sarotalocan run by Aura Biosciences, completed.
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma is a phase 2 interventional study registered as NCT04417530 by Aura Biosciences, with 22 participants enrolled, started 2020-08-05. Conditions recorded: Uveal Melanoma, Ocular Melanoma and Choroidal Melanoma. Interventions recorded: AU-011, Suprachoroidal Microinjector and PDT Laser.
Shares Aura Biosciences, Belzupacap sarotalocan, Uveal melanoma and the tag pipeline.
Shares Aura Biosciences, Belzupacap sarotalocan, Uveal melanoma and the tag pipeline.
Shares Aura Biosciences, Belzupacap sarotalocan and the tag pipeline.
Shares Aura Biosciences, Belzupacap sarotalocan and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/